Evaluation of functional erythropoietin receptor status in skeletal muscle in vivo: Acute and prolonged studies in healthy human subjects

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Christensen, Britt ^a,b   Lundby, Carsten ^c   Jessen, Niels ^a,b   Nielsen, Thomas S ^b   Vestergaard, Poul F ^a,b   Møller, Niels ^a,b   Pilegaard, Henriette ^e   Pedersen, Steen B ^a   Kopchick, John J ^d   Jørgensen, Jens Otto L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d OHIO UNIVERSITY   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CREATINE KINASE; DESMIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GROWTH HORMONE; I KAPPA B; I KAPPA B KINASE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN LIGHT CHAIN; PLACEBO; PROTEIN KINASE B; PROTEOME; RECOMBINANT ERYTHROPOIETIN; S6 KINASE; SOMATOMEDIN B; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; ISOPROTEIN; MESSENGER RNA; OXYGEN; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME ACTIVATION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MUSCLE BIOPSY; MUSCLE TISSUE; NORMAL HUMAN; PROTEIN CONTENT; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKELETAL MUSCLE; TWO DIMENSIONAL GEL ELECTROPHORESIS; VASTUS LATERALIS MUSCLE; WESTERN BLOTTING; BIOPSY; METABOLISM; METHODOLOGY; PHOSPHORYLATION; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROTEOMICS; SIGNAL TRANSDUCTION; TIME;

ADULT; BIOPSY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ERYTHROPOIETIN; HUMANS; MALE; MASS SPECTROMETRY; MUSCLE, SKELETAL; OXYGEN; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; PROTEOMICS; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84857469947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031857     Document Type: Article

References (37)

1. Fisher JW, (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228: 1-14.
2. Chong ZZ, Kang JQ, Maiese K, (2003) Erythropoietin: cytoprotection in vascular and neuronal cells. Curr Drug Targets Cardiovasc Haematol Disord 3: 141-154.
3. Constantinescu SN, Ghaffari S, Lodish HF, (1999) The Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction. Trends Endocrinol Metab 10: 18-23.
4. Tilbrook PA, Klinken SP, (1999) The erythropoietin receptor. Int J Biochem Cell Biol 31: 1001-1005.
5. Jelkmann W, (2004) Molecular biology of erythropoietin. Intern Med 43: 649-659.
6. Jelkmann W, (2007) Erythropoietin after a century of research: younger than ever. Eur J Haematol 78: 183-205.
7. Lappin TR, Maxwell AP, Johnston PG, (2002) EPO's alter ego: erythropoietin has multiple actions. Stem Cells 20: 485-492.
8. Feng Q, (2006) Beyond erythropoiesis: the anti-inflammatory effects of erythropoietin. Cardiovasc Res 71: 615-617.
9. Erbayraktar S, Yilmaz O, Gokmen N, Brines M, (2003) Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep 2: 465-470.
10. Marzo F, Lavorgna A, Coluzzi G, Santucci E, Tarantino F, et al. (2008) Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 26: 183-187.
11. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, et al. (2004) Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18: 1031-1033.
12. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, et al. (2000) Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 275: 39754-39761.
13. Lundby C, Hellsten Y, Jensen MB, Munch AS, Pilegaard H, (2008) Erythropoietin receptor in human skeletal muscle and the effects of acute and long term injections with recombinant human erythropoietin on the skeletal muscle. J Appl Physiol 104: 1154-1160.
14. Rundqvist H, Rullman E, Sundberg CJ, Fischer H, Eisleitner K, et al. (2009) Activation of the erythropoietin receptor in human skeletal muscle. Eur J Endocrinol 161: 427-434.
15. Lundby C, Olsen NV, (2011) Effects of recombinant humant erythropoietin in normal humans. J Physiol 589: 1265-1271.
16. Juel C, Thomsen JJ, Rentsch RL, Lundby C, (2007) Effects of prolonged recombinant human erythropoietin administration on muscle membrane transport systems and metabolic marker enzymes. Eur J Appl Physiol 102: 41-44.
17. Cayla JL, Maire P, Duvallet A, Wahrmann JP, (2008) Erythropoietin induces a shift of muscle phenotype from fast glycolytic to slow oxidative. Int J Sports Med 29: 460-465.
18. Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, et al. (1998) Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood 91: 3734-3745.
19. Boudot C, Dasse E, Lambert E, Kadri Z, Mayeux P, et al. (2003) Involvement of the Src kinase Lyn in phospholipase C-gamma 2 phosphorylation and phosphatidylinositol 3-kinase activation in Epo signalling. Biochem Biophys Res Commun 300: 437-442.
20. Bittorf T, Buchse T, Sasse T, Jaster R, Brock J, (2001) Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance. Cell Signal 13: 673-681.
21. Jegalian AG, Wu H, (2002) Differential roles of SOCS family members in EpoR signal transduction. J Interferon Cytokine Res 22: 853-860.
22. Christensen B, Sackmann-Sala L, Cruz-Topete D, Jorgensen JO, Jessen N, et al. (2011) Novel serum biomarkers for erythropoietin use in humans: A proteomic approach. J Appl Physiol 110: 149-156.
23. Jorgensen JO, Jessen N, Pedersen SB, Vestergaard E, Gormsen L, et al. (2006) GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. Am J Physiol Endocrinol Metab 291: E899-E905.
24. Launay T, Hagstrom L, Lottin-Divoux S, Marchant D, Quidu P, et al. (2010) Blunting effect of hypoxia on the proliferation and differentiation of human primary and rat L6 myoblasts is not counteracted by Epo. Cell Prolif 43: 1-8.
25. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, et al. (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107: 1892-1895.
26. Kirkeby A, van BJ, Nielsen J, Leist M, Helboe L, (2007) Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci Methods 164: 50-58.
27. LeBaron MJ, Ahonen TJ, Nevalainen MT, Rui H, (2007) In vivo response-based identification of direct hormone target cell populations using high-density tissue arrays. Endocrinology 148: 989-1008.
28. Hagstrom L, Agbulut O, El-Hasnaoui-Saadani R, Marchant D, Favret F, et al. (2010) Epo is relevant neither for microvascular formation nor for the new formation and maintenance of mice skeletal muscle fibres in both normoxia and hypoxia. J Biomed Biotechnol 2010: 137817.
29. Rotter R, Menshykova M, Winkler T, Matziolis G, Stratos I, et al. (2008) Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue. J Orthop Res 26: 1618-1626.
30. Ren CL, Morio T, Fu SM, Geha RS, (1994) Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med 179: 673-680.
31. Tilbrook PA, Colley SM, McCarthy DJ, Marais R, Klinken SP, (2001) Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells. Arch Biochem Biophys 396: 128-132.
32. Schmidt EK, Fichelson S, Feller SM, (2004) PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors. BMC Biol 2: 7.
33. Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, et al. (2010) Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res 8: 615-626.
34. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ, (2004) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 44: 991-1002.
35. Okumura N, Hashida-Okumura A, Kita K, Matsubae M, Matsubara T, et al. (2005) Proteomic analysis of slow- and fast-twitch skeletal muscles. Proteomics 5: 2896-2906.
36. Staron RS, Johnson P, (1993) Myosin polymorphism and differential expression in adult human skeletal muscle. Comp Biochem Physiol B 106: 463-475.
37. Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, et al. (2009) Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One 4: e5894.